DEPAKENE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Depakene, and when can generic versions of Depakene launch?
Depakene is a drug marketed by Abbvie and is included in two NDAs.
The generic ingredient in DEPAKENE is valproic acid. There are seventeen drug master file entries for this compound. Fifteen suppliers are listed for this compound. Additional details are available on the valproic acid profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Depakene
A generic version of DEPAKENE was approved as valproic acid by CATALENT on October 29th, 1991.
Summary for DEPAKENE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 144 |
| Clinical Trials: | 23 |
| Patent Applications: | 3,719 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for DEPAKENE |
| DailyMed Link: | DEPAKENE at DailyMed |
Recent Clinical Trials for DEPAKENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cancer Prevention Research Institute of Texas | Phase 2/Phase 3 |
| M.D. Anderson Cancer Center | Phase 2/Phase 3 |
| Kimberly S Jones | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for DEPAKENE
US Patents and Regulatory Information for DEPAKENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie | DEPAKENE | valproic acid | CAPSULE;ORAL | 018081-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Abbvie | DEPAKENE | valproic acid | SYRUP;ORAL | 018082-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
